#POS0709 #EULAR2022 Pooled analyses of TULIP-1 & -2 RCTs showed sustained & #lupus patients spent longer time in BICLA response vs Placebo up to 52 Wks. BILAG response was sustained in MSK, skin and constitutional domains. Be interesting to see longer follow-up data @RheumNow https://t.co/kNk7WFloLf

Watch: EULAR Recommendations for ANCA Vasculitis Dr. Eric Dein reviews the session held on updates to recommendations for ANCA Vasculitis, presented at the #EULAR2022 meeting in June. https://t.co/1nr0tVIJpn https://t.co/kq0Id7PxyW

A Big Leap in Modulating Rheumatoid Disease Intervention in individuals predisposed to develop rheumatoid arthritis (RA), with a holy grail of prevention of RA, has long been a hot topic. https://t.co/QHK7c3Qhz6 https://t.co/jFR9wDCD8o

CTD associated ILD 🫁: lncRNA ENST00000604692 detected in PBMCs is associated with CTD-ILD and can distinguish SSc- ILD and RA-ILD vs. non ILD patients with AUC 0.79. As many lncRNA, unknown if biomarker only or has a pathogenic role. @RheumNow OP0114 #EULAR2022 https://t.co/sR4GmaMkXD

Lung 🫁 cancer incidence and RA 44000+ RA (EIRA prospective cohort) and 216000+ matched Ctrls Swedish registries 📍56 per 100,000 📍HR 1.77 (adjusted for smoking 🚬) 📍Risk in RA + smoking 7x higher 📍Risk 2x in Sero+ vs. sero- No data on ttmt #EULAR2022 @RheumNow POS0061 https://t.co/c7eh3icW2c

B-cell depletion w/ RTX ttmt is FcγR dependant & affected by FcγRs variants 🧬 FCGR3A-158V: *encodes the allotype ⬆️ affinity for IgG1 *is associated w/ clinical and biological responses in RA and SLE. A new way to stratify pts for anti-CD20 therapy? @Yuz6Yusof #EULAR2022 OP0190 https://t.co/GPiaQXaF71

Great meeting @RheumNow. He does a great job of educating Rheumatologists around the world especially through his podcast. Great discussion on the usefulness of ultrasound for Rheumatologists #EULAR2022 https://t.co/0hw7mpX8dm

Pascual et al. Anti-TIF1gamma and cancer risk in DM and non-DM. Cancer in 60% of DM and 21% of non-DM patients with Anti-TIF1gamma https://t.co/OxKdlmDBBD

Kristensen et al. 52 week results KEEPsAKE 1 RCT risankizumab vs PBO to week 24, then rescue, in csDMARD-IR PsA. ACR20 57% vs 34% (PBO) week 24, week 52 70%/63% ACR20. ACR 50/70 similar differences. PASI even better. @RheumNow #EULAR2022 POS1024 https://t.co/USQsMQ7oxu

Vadillo et al. Clinical course in IPAF (ping @leticiakawano ) . Most frequent females in 60s. Arthritis, raynauds most common features. Most NSIP. 50% PFT deterioration 16 months. UIP, baseline fibrosis, mod/high ANA titre assoc progression @RheumNow #EULAR2022 POS1427 https://t.co/qk9zK90Wuk

Large French study of over 23k patients with either PsA or PsO showed a longer persistence (time of initiation to discontinuation) in those who took IL-17i vs. TNFi for PsA and PsO pts. IL-17i longer than IL-12/23i in PsA pts. @RheumNow #EULAR2022 ABST#POS0075 https://t.co/rH1g4fPUYC